+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Atopic Dermatitis Drugs Market - Global Forecast 2026-2032- Product Image
Atopic Dermatitis Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Atopic Dermatitis Drugs Market - Global Forecast 2026-2032

  • Report

  • 192 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4904629
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Atopic Dermatitis Drugs Market is projected to reach USD 18.30 Billion in 2026. It is expected to continue growing at a CAGR of 9.11%, reaching USD 30.99 Billion by 2032.

Atopic dermatitis drugs are moving from symptom control toward targeted, disease-modifying management of chronic type 2 inflammation, itch, sleep disruption, skin barrier dysfunction, and recurrent flares. The treatment landscape spans topical corticosteroids, topical calcineurin inhibitors, phosphodiesterase-4 inhibitors, topical Janus kinase (JAK) inhibitors, systemic immunosuppressants, biologics, and oral JAK inhibitors used in moderate-to-severe disease.

Demand is supported by a large clinical burden: peer-reviewed dermatology literature consistently reports that atopic dermatitis affects up to about 20% of children and up to about 10% of adults in many populations, with meaningful quality-of-life impact related to pruritus, sleep loss, anxiety, infection risk, and productivity impairment. The market is being reshaped by higher diagnosis rates, guideline adoption, payer scrutiny, pediatric label expansions, and the growing expectation that therapies should reduce itch rapidly while sustaining long-term skin clearance and safety.

Transformative Shifts in the Atopic Dermatitis Treatment Landscape

The most important shift in the atopic dermatitis drugs landscape is the move from broad anti-inflammatory treatment to precision immunology. Interleukin-4 and interleukin-13 pathway inhibition has established a major standard for moderate-to-severe disease, while interleukin-13-specific targeting has further refined biologic treatment options. Oral JAK inhibitors in approved markets have added rapid itch and lesion control, but boxed warnings, laboratory monitoring, contraindications, and risk management requirements have sharpened the importance of patient selection and long-term safety surveillance.

Topical innovation is also changing treatment sequencing. Nonsteroidal options such as phosphodiesterase-4 inhibition and topical JAK inhibition address steroid-sparing needs, while newer formulations seek better tolerability, adherence, and use in sensitive body areas. As payers compare acquisition cost, durability, safety, and real-world outcomes, manufacturers are increasingly required to demonstrate value through comparative evidence, patient-reported outcomes, flare reduction, sleep improvement, and reduced healthcare utilization.

Cumulative Impact of Artificial Intelligence on Atopic Dermatitis Drugs

Artificial intelligence is beginning to influence the atopic dermatitis drugs market across discovery, development, commercialization, and care delivery. In drug discovery, AI-enabled target identification and molecular modeling are helping developers evaluate cytokine networks, JAK selectivity, skin-barrier biology, microbiome interactions, and itch pathways more efficiently. In clinical development, machine learning can support trial site selection, eligibility matching, endpoint prediction, and stratification of patients by disease severity, biomarkers, comorbidity patterns, prior treatment exposure, and likelihood of response.

The cumulative impact is expected to be strongest in real-world evidence generation and personalized treatment pathways. AI-assisted image analysis can standardize lesion severity assessments, while digital tools can track flares, sleep loss, itch intensity, adherence, treatment response, and adverse events between visits. For industry leaders, the opportunity is not simply automation; it is building evidence ecosystems that connect dermatology workflows, patient-reported outcomes, pharmacovigilance, health economics, and payer-relevant value metrics.

Key Regional Insights for Atopic Dermatitis Drugs

North America remains a high-value region for atopic dermatitis drugs because of specialist access, biologic adoption, specialty pharmacy infrastructure, commercial insurance coverage, and strong uptake of new mechanisms after regulatory approval. The United States drives much of the regional innovation and demand through rapid launch activity and broad clinical trial participation, while Canada emphasizes reimbursement review, clinical evidence, and equitable access across provincial systems.

Europe is characterized by mature dermatology guidelines, centralized regulatory evaluation, national health technology assessment processes, and careful cost-effectiveness review for biologics, oral JAK inhibitors, and advanced topical therapies. Asia-Pacific is expanding as China, Japan, South Korea, India, Australia, and ASEAN markets address rising diagnosis, urbanization-linked allergic disease burden, expanding specialty care, and broader access to immunology-based treatment. Latin America, led by Brazil and Mexico, shows growing demand for advanced eczema therapies but faces affordability, reimbursement, and public-sector access constraints. The Middle East, especially GCC markets, benefits from high healthcare investment, tertiary specialist centers, and premium therapy adoption, while Africa remains underpenetrated due to limited specialist density, diagnostic gaps, access constraints, and continued reliance on essential topical therapies.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are becoming increasingly relevant as urban populations, private hospital networks, dermatology awareness, and allergy-related disease recognition expand, although access remains uneven across Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. GCC countries are positioned for faster adoption of biologics and advanced therapies due to specialist infrastructure, national health investments, government-backed care models, and a preference for innovative branded medicines in tertiary care.

The European Union is a critical evidence-led market where regulatory approval, pharmacoeconomic review, prescribing guidance, and post-marketing data strongly shape adoption. BRICS countries represent scale and long-term demand, led by China, India, and Brazil, but pricing, reimbursement, local evidence generation, and manufacturing strategies are central to success. G7 markets continue to set the benchmark for clinical standards, regulatory rigor, premium access evidence, and launch sequencing. NATO countries, while not a healthcare bloc, overlap with many high-income markets where medicine security, supply resilience, pharmacovigilance coordination, and regulatory alignment increasingly influence pharmaceutical strategy.

Key Country Insights for Atopic Dermatitis Drugs

The United States is the central commercialization market for atopic dermatitis drugs, supported by FDA pathways, specialty pharmacy infrastructure, patient awareness, high biologic utilization, and strong demand for targeted oral and topical innovation. Canada follows a more evidence- and reimbursement-driven model, while Mexico shows growing private-market use of advanced therapies alongside broader reliance on conventional topical treatments. Brazil leads Latin America in dermatology scale and biologic access, although public reimbursement, affordability, and regional care variation remain decisive.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine robust dermatology expertise with payer scrutiny, making comparative effectiveness, guideline alignment, and real-world outcomes essential. Russia has demand for dermatology therapies but faces access, reimbursement, and supply-chain complexity. China is rapidly expanding as regulatory modernization, local innovation, and specialty care improve, while India offers large patient volume but remains highly price-sensitive with significant use of topical and generic therapies. Japan has strong dermatology standards and early adoption of selected advanced therapies, Australia benefits from structured reimbursement and specialist access, and South Korea combines advanced healthcare infrastructure with growing demand for targeted immunology treatments.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical value rather than mechanism novelty alone. The strongest opportunities lie in therapies that demonstrate rapid itch relief, durable eczema control, safe long-term use, pediatric utility, steroid-sparing benefits, lower flare frequency, and performance in difficult-to-treat areas such as the face, hands, eyelids, and intertriginous skin.

Organizations should invest in real-world evidence, payer-aligned outcomes, and digital adherence programs that document reduced flares, fewer physician visits, improved sleep, better quality of life, and lower corticosteroid burden. Market access strategies should be tailored by region: premium evidence packages for the United States, G7, and EU; affordability, local evidence, and partnership models for BRICS and Latin America; and specialist education plus formulary engagement in ASEAN, GCC, Middle Eastern, and emerging African markets.

Research Methodology

This executive summary is developed using a structured secondary research approach aligned with pharmaceutical market intelligence standards. The analysis synthesizes publicly available regulatory information, dermatology guidelines, peer-reviewed clinical literature, product labels where available, health technology assessment patterns, clinical trial registries, pharmacovigilance considerations, and recognized epidemiology sources for atopic dermatitis prevalence, severity, comorbidities, and treatment pathways.

Insights are validated through triangulation across clinical, commercial, and policy dimensions, including mechanism-of-action trends, regional access conditions, reimbursement dynamics, competitive positioning, patient-reported outcomes, safety requirements, and real-world evidence needs. The methodology emphasizes verified, data-backed interpretation and avoids unsupported market sizing, market share, or forecasting where consistent public estimates are not available.

Conclusion

The atopic dermatitis drugs market is entering a more competitive and evidence-intensive phase. Targeted biologics, oral JAK inhibitors, and advanced topical therapies are expanding treatment possibilities beyond conventional topical corticosteroids and systemic immunosuppressants, while safety, access, adherence, and cost-effectiveness continue to shape prescribing decisions.

Future leadership will depend on integrated strategies that combine clinical differentiation, patient-centric outcomes, AI-enabled evidence generation, and region-specific market access execution. Developers that can prove durable disease control, improve quality of life, support safe long-term use, and address affordability across diverse health systems will be best positioned in the global atopic dermatitis therapeutics landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Atopic Dermatitis Drugs Market, by Drug Class
7.1. Introduction
7.2. Systemic
7.2.1. Biologics
7.2.2. Small Molecule Immunosuppressants
7.3. Topical
7.3.1. Calcineurin Inhibitors
7.3.2. Corticosteroids
7.3.3. PDE4 Inhibitors
7.3.4. Vitamin D Analogues
8. Atopic Dermatitis Drugs Market, by Route Of Administration
8.1. Introduction
8.2. Cream
8.3. Gel
8.4. Lotion
8.5. Ointment
9. Atopic Dermatitis Drugs Market, by Mode Of Administration
9.1. Introduction
9.2. Injectable
9.2.1. Pre Filled Syringes
9.2.2. Vials
9.3. Oral
10. Atopic Dermatitis Drugs Market, by Patient Age Group
10.1. Introduction
10.2. Adult
10.3. Geriatric
10.4. Pediatric
11. Atopic Dermatitis Drugs Market, by End User
11.1. Introduction
11.2. Hospitals
11.3. Dermatology Clinics
11.4. Homecare
12. Atopic Dermatitis Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.3.1. Digital Health Platforms
12.3.2. E Commerce Platforms
12.4. Retail Pharmacies
13. Atopic Dermatitis Drugs Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Atopic Dermatitis Drugs Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Atopic Dermatitis Drugs Market, by Country
15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. AbbVie Inc.
17.2. Amgen Inc.
17.3. Arcutis Biotherapeutics, Inc.
17.4. AstraZeneca PLC
17.5. Avanti’s Skin and Laser Clinic
17.6. Bausch Health Companies Inc.
17.7. Bayer AG
17.8. Biofrontera AG
17.9. Bristol-Myers Squibb Company
17.10. Chugai Pharmaceutical Co., Ltd.
17.11. Daavlin Company
17.12. Eli Lilly and Company
17.13. F. Hoffmann-La Roche Ltd.
17.14. Galderma Holding SA
17.15. GlaxoSmithKline PLC
17.16. Incyte Corporation
17.17. Johnson & Johnson Services Inc.
17.18. LEO Pharma A/S
17.19. Maruho Co., Ltd
17.20. Novartis AG
17.21. Organon & Co.
17.22. Otsuka Pharmaceutical Co., Ltd.
17.23. Perrigo Company PLC
17.24. Pfizer, Inc.
17.25. Regeneron Pharmaceuticals, Inc
17.26. Sanofi SA
17.27. Solarc Systems Inc.
17.28. Teva Pharmaceutical Industries Ltd.
17.29. Torii Pharmaceutical Co., Ltd.
17.30. UCB S.A.
17.31. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL ATOPIC DERMATITIS DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ATOPIC DERMATITIS DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ATOPIC DERMATITIS DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ATOPIC DERMATITIS DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL ATOPIC DERMATITIS DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL SYSTEMIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL SYSTEMIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL SYSTEMIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL SMALL MOLECULE IMMUNOSUPPRESSANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL SMALL MOLECULE IMMUNOSUPPRESSANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL SMALL MOLECULE IMMUNOSUPPRESSANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL PDE4 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL PDE4 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL PDE4 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL VITAMIN D ANALOGUES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL VITAMIN D ANALOGUES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL VITAMIN D ANALOGUES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL CREAM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL CREAM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL CREAM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL GEL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL GEL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL GEL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL LOTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL LOTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL LOTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL OINTMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL OINTMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL OINTMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL PRE FILLED SYRINGES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL PRE FILLED SYRINGES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PRE FILLED SYRINGES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL VIALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL VIALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL VIALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ADULT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ADULT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL DERMATOLOGY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL DERMATOLOGY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL DERMATOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL DIGITAL HEALTH PLATFORMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL DIGITAL HEALTH PLATFORMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL DIGITAL HEALTH PLATFORMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL E COMMERCE PLATFORMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL E COMMERCE PLATFORMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL E COMMERCE PLATFORMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 102. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 104. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 105. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 106. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 107. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 108. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 109. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 110. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 111. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 112. EUROPE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 115. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 116. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 117. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 118. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 119. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 124. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 126. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 127. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 128. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 129. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 130. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 131. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 134. LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 135. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 136. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 137. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 138. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 139. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 140. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 141. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 142. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 143. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 145. AFRICA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 147. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 148. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 149. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 150. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 151. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 152. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 153. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 154. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 155. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 156. MIDDLE EAST ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 158. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 159. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 160. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 161. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 162. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 163. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 164. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 165. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 166. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 167. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 168. NATO ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 169. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 170. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 171. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 172. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 173. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 174. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 175. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 176. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 177. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 178. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 179. G7 ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 180. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 181. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 182. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 183. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 184. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 185. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 186. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 187. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 188. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 189. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 190. BRICS ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 202. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 203. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 204. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 205. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 206. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 207. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 208. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 209. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 210. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 211. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 212. ASEAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 213. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 214. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 215. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 216. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 217. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 218. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 219. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 220. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 221. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 222. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 223. GCC ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 224. GLOBAL ATOPIC DERMATITIS DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 225. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 226. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 227. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 228. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 229. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 230. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 231. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 232. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 233. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 234. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 235. CHINA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 242. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 243. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 244. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 245. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 246. UNITED STATES ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 247. JAPAN ATOPIC DERMATITIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 248. JAPAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 249. JAPAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 250. JAPAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 251. JAPAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 252. JAPAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 253. JAPAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 254. JAPAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 255. JAPAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 256. JAPAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 257. JAPAN ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 258. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 259. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 260. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 261. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 262. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 263. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 264. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 265. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 266. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 267. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 268. INDIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 269. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 270. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 271. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 272. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 273. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 274. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 275. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 276. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 277. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 278. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 279. GERMANY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 280. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 281. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 282. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 283. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 284. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 285. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 286. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 287. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 288. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 290. UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 291. AUSTRALIA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 292. AUSTRALIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 293. AUSTRALIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 294. AUSTRALIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 295. AUSTRALIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 296. AUSTRALIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 297. AUSTRALIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 298. AUSTRALIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 299. AUSTRALIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 300. AUSTRALIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 301. AUSTRALIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 302. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 303. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 304. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 305. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 306. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 307. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 308. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 309. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 310. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 311. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 312. FRANCE ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 313. SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 314. SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 315. SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 316. SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 317. SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 318. SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 319. SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 320. SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 321. SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 322. SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 323. SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 324. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 325. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 326. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 327. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 328. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 329. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 330. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 331. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 332. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 333. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 334. ITALY ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 335. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 336. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 337. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 338. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 339. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 340. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 341. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 342. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 343. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 344. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 345. CANADA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2017-2032 (USD MILLION)
TABLE 346. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 347. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 348. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY SYSTEMIC, 2017-2032 (USD MILLION)
TABLE 349. RUSSIA ATOPIC DERMATITIS DRUGS MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 350. RUSSIA ATOPIC DERMATITIS DRUGS

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Arcutis Biotherapeutics, Inc.
  • AstraZeneca PLC
  • Avanti’s Skin and Laser Clinic
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biofrontera AG
  • Bristol-Myers Squibb Company
  • Chugai Pharmaceutical Co., Ltd.
  • Daavlin Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Galderma Holding SA
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Johnson & Johnson Services Inc.
  • LEO Pharma A/S
  • Maruho Co., Ltd
  • Novartis AG
  • Organon & Co.
  • Otsuka Pharmaceutical Co., Ltd.
  • Perrigo Company PLC
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc
  • Sanofi SA
  • Solarc Systems Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Torii Pharmaceutical Co., Ltd.
  • UCB S.A.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages192
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 18.3 Billion
Forecasted Market Value ( USD ) by 2032 $ 30.99 Billion
Compound Annual Growth Rate9.1%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Atopic Dermatitis Drugs - Global Strategic Business Report - Product Image

Atopic Dermatitis Drugs - Global Strategic Business Report

  • Report
  • 351 Pages
  • Global
From
Canine Atopic Dermatitis Market Report by Drug Class Type, Route of Administration, Distribution Channel, and Region 2026-2034 - Product Image

Canine Atopic Dermatitis Market Report by Drug Class Type, Route of Administration, Distribution Channel, and Region 2026-2034

  • Report
  • 141 Pages
  • Global
From
Atopic Dermatitis Market Outlook 2026-2034: Market Share and Growth Analysis by Drug Class, Route of Administration, Patient Age Group, Distribution Channel - Product Image

Atopic Dermatitis Market Outlook 2026-2034: Market Share and Growth Analysis by Drug Class, Route of Administration, Patient Age Group, Distribution Channel

  • Report
  • 160 Pages
  • Global
From
Atopic Dermatitis - Competitive Landscape, 2026 - Product Image

Atopic Dermatitis - Competitive Landscape, 2026

  • Report
  • 240 Pages
  • Global
From
Atopic Dermatitis Clinical Trials - Global Strategic Business Report - Product Image

Atopic Dermatitis Clinical Trials - Global Strategic Business Report

  • Report
  • 216 Pages
  • Global
From

About the Market

The Eczema Drug market is a subset of the Dermatological Drugs market, which includes medications used to treat skin conditions. Eczema drugs are used to treat the symptoms of eczema, a chronic skin condition characterized by red, itchy, and inflamed skin. These drugs are typically topical creams, ointments, and lotions, and may contain corticosteroids, calcineurin inhibitors, and other active ingredients. In addition to treating the symptoms of eczema, these drugs may also help to reduce the risk of infection and improve the overall quality of life for those affected by the condition. Some companies in the Eczema Drug market include GlaxoSmithKline, Pfizer, Novartis, Sanofi, and Mylan. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.